Alternative Antifungal Agents to Fluconazole

Primary Alternatives by Clinical Scenario

The Infectious Diseases Society of America (IDSA) guidelines recommend echinocandins (caspofungin, micafungin, or anidulafungin) as the preferred first-line alternatives to fluconazole for moderately severe to critically ill patients with invasive candidiasis and candidemia 1, 2, 3
For candidemia and invasive candidiasis, caspofungin is recommended at a dose of 70 mg loading dose, then 50 mg daily 1, 2, 3
For candidemia and invasive candidiasis, micafungin is recommended at a dose of 100 mg daily 1, 2, 3
For candidemia and invasive candidiasis, anidulafungin is recommended at a dose of 200 mg loading dose, then 100 mg daily 1, 2, 3
The IDSA guidelines specifically favor echinocandins over fluconazole for patients with moderate-to-severe illness or recent azole exposure, due to their fungicidal activity and broader coverage against azole-resistant species 1, 2, 3, 4
Lipid formulation amphotericin B (3-5 mg/kg daily) serves as a reasonable second-line alternative when there is intolerance, limited availability, or resistance to both azoles and echinocandins, particularly for azole- and echinocandin-resistant Candida infections 2, 3, 5
Voriconazole (400 mg twice daily for 2 doses, then 200 mg twice daily) is effective for candidemia but offers little advantage over fluconazole as initial therapy, although it is recommended as step-down oral therapy for C. krusei infections 2, 3, 5

For Candida krusei infections, which have intrinsic resistance to fluconazole, alternatives include echinocandins (preferred), lipid formulation amphotericin B, and voriconazole 3, 6
For Candida glabrata infections, which often have reduced susceptibility to fluconazole, echinocandins are preferred for initial therapy, and transition to fluconazole or voriconazole should not occur without documented susceptibility testing 2, 4, 5
For Candida parapsilosis infections, while echinocandins have reduced activity, they remain reasonable options if clinical improvement occurs and follow-up cultures are negative 4

Fluconazole should not be used for C. krusei infections (intrinsically resistant), suspected or confirmed azole-resistant infections, critically ill patients as initial empiric therapy, or patients with recent azole exposure 1, 2, 4, 5, 8
Amphotericin B deoxycholate has significant nephrotoxicity and its use is limited, although lipid formulations have improved safety profiles but are more expensive 6
Respiratory tract colonization with Candida usually represents colonization, not infection, and rarely requires antifungal treatment 6, 8